Catecholquinones as substrates of the NRH: Quinone oxidoreductase 2 in the brain and retina

Quinones: Occurrence, Medicinal Uses and Physiological Importance

Volumn , Issue , 2013, Pages 141-156

  Sampaio, Lucia De Fatima Sobral ^a  

^a Para Federal University   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895407067     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (69)

1. Ahn, K. S., Gong, X., Sethi, G., Chaturvedi, M. M., Jaiswal, A. K. and Aggarwal, B. B. (2007). Deficiency of NRH:quinone oxidoreductase 2 differentially regulates TNF signaling in keratinocytes: up-regulation of apoptosis correlates with down-regulation of cell survival kinases. Cancer Res, 67, 10004-10011.
2. Asanuma, M., Miyazaki, I., Diaz-Corrales, F. J. and Ogawa N. (2004). Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med Okayama, 58, 221-233.
3. Asanuma, M., Miyazaki, I., Diaz-Corrales, F. J., Miyoshi, K., Ogawa, N. and Murata, M. (2008). Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci Res, 60, 106-113.
4. Asanuma, M., Miyazaki, I., Kikkawa, Y., Kimoto, N., Takeshima, M., Murakami, S and Miyoshi, K. (2012). Cyclooxygenase-independent neuroprotective effects of aspirin against dopamine quinone-induced neurotoxicity. Neurochem Res, 37, 1944-1951.
5. Bagh, M. B., Maiti, A. K., Jana, S., Banerjee, K., Roy, A. and Chakrabarti, S. (2008). Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson's disease. Free Radic Res, 42, 574-581.
6. Benoit, C. E., Bastianetto, S., Brouillette, J., Tse, Y. Boutin, J. A., Delagrange, P., Wong, T., Sarret, P. and Quirion, R. (2010) Loss of quinone reductase 2 function selectively facilitates learning behaviors. J Neurosci, 30, 12690-12700.
7. Calamini, B., Santarsiero, B. D., Boutin, J. A. and Mesecar, A. D. (2008). Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem J, 413, 81-91.
8. Cavalieri, E. L., Li, K. M., Balu, N., Saeed, M., Devanesan, P., Higginbotham, S., Zhao, J., Gross, M. L. and Rogan, E. G. (2002). Catechol orthoquinones:the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis, 23, 1071-1077.
9. Cavalieri, E. L. and Rogan, E. G. (2011). Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol, 125, 169-180.
10. Conway, K. A., Rochet, J. C., Bieganski, R. M. and Lansbury, P. T. Jr. (2001). Kinetic stabilization of the alpha-synuclein protofibril by a dopaminealpha-synuclein adduct. Science, 294, 1346-1349.
11. Durcan, T. M., Kontogiannea, M., Thorarinsdottir, T., Fallon, L., Williams, A. J., Djarmati, A., Fantaneanu, T., Paulson, H. L. and Fon, E. A. (2011). The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. Hum Mol Genet, 20, 141-154.
12. Celli, C. M., Tran, N., Knox, R. and Jaiswal, A. K. (2006). NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem. Pharmacol, 72, 366-376.
13. Chakraborty, A. K., Ichihashi, M. and Mishima, Y. (1991). Effect of dopaloading on glutathione metabolising enzymes and tyrosinase in relation to 5-S-cysteinyl-dopa genesis in cultured B-16 melanoma cells. J Dermatol Sci, 2, 329-335.
14. Eisenhofer, G., Kopin, I. J. and Goldstein, D. S. (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev, 56, 331-349.
15. Fallon, L., Moreau, F., Croft, B. G., Labib, N., Gu, W. J. and Fon, E. A. (2002). Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. J Biol Chem, 277, 486-491.
16. Fallon, L., Bélanger, C. M., Corera, A. T., Kontogiannea, M., Regan-Klapisz, E., Moreau, F., Voortman, J., Haber, M., Rouleau, G., Thorarinsdottir, T., Brice, A., van Bergen En Henegouwen, P. M. and Fon, E. A. (2006) A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol, 8, 834-842.
17. Fu, Y., Buryanovskyy, L. and Zhang, Z. (2008). Quinone reductase 2 is a catechol quinone reductase. J Biol Chem, 283, 23829-23835.
18. Graham, D. G. (1978). Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol, 14, 633-643.
19. Graham, D. G., Tiffany, S. M., Bell, W. R. Jr. and Gutknecht, W. F. (1978). Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol, 14, 644-653.
20. Gomez Sarosi, L. A., Rieber, M. S. and Rieber, M. (2003). Hydrogen peroxide increases a 55-kDa tyrosinase concomitantly with induction of p53-dependent p21 waf1 expression and a greater Bax/Bcl-2 ratio in pigmented melanoma. Biochem Biophys Res Commun, 312, 355-359.
21. Gong, X., Kole, L., Iskander, K. and Jaiswal, A. K. (2007). NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res, 67, 5380-5388.
22. Gong, X., Gutala, R. and Jaiswal, A. K. (2008). Quinone oxidoreductases and vitamin K metabolism. Vitam Horm, 78, 85-101.
23. Hanna, C. (1965). Metabolism of catecholamines. Invest Ophthalmol, 4, 1095-1104.
24. Hashimoto, T. and Nakai, M. (2011). Increased hippocampal quinone reductase 2 in Alzheimer's disease. Neurosci Lett. 502, 10-12.
25. Hsieh, T. C., Wang, Z., Hamby, C. V. and Wu, J. M. (2005). Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem Biophys Res Commun, 334, 223-230.
26. Iskander, K., Paquet, M., Brayton, C. and Jaiswal, A. K. (2004). Deficiency of NRH:quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res, 64, 5925-5928.
27. Iskander, K. and Jaiswal, A. K. (2005). Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity. Chem Biol Interact, 153, 147-157.
28. Iskander, K., Li, J., Han, S., Zheng, B. and Jaiswal, A. K. (2006). NQO1 and NQO2 regulation of humoral immunity and autoimmunity. J. Biol. Chem, 281, 30917-30924.
29. Iskander, K., Barrios, R. J. and Jaiswal, A. K. (2009). NRH:quinone oxidoreductase 2-deficient mice are highly susceptible to radiationinduced B-cell lymphomas. Clin Cancer Res, 15, 1534-1542.
30. Jamieson, D., Wilson, K., Pridgeon, S., Margetts, J. P., Edmondson, R. J., Leung, H. Y., Knox, R. and Boddy, A. V. (2007). NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 singlenucleotide polymorphism. Clin Cancer Res, 13, 1584-1590.
31. Jaiswal, A. K. (1994). Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression. J Biol Chem, 269, 14502-140508.
32. Jefcoate, C. R., Liehr, J. G., Santen, R. J., Sutter, T. R., Yager, J. D., Yue, W., Santner, S. J., Tekmal, R., Demers, L., Pauley, R., Naftolin, F., Mor, G. and Berstein L. (2000). Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr, 2000, 95-112.
33. Kwiek, J. J., Haystead, T. A. and Rudolph, J. (2004). Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry, 43, 4538-4547.
34. LaVoie, M. J., Cortese, G. P., Ostaszewski, B. L. and Schlossmacher, M. G. (2007). The effects of oxidative stress on parkin and other E3 ligases. J Neurochem; 103, 2354-2368.
35. LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G. and Selkoe, D. J. (2005). Dopamine covalently modifies and functionally inactivates parkin. Nat Med, 11, 1214-1221.
36. Long, D. J. 2nd and Jaiswal, A. K. (2000). Mouse NRH:quinone oxidoreductase (NQO2): cloning of cDNA and gene- and tissue-specific expression. Gene, 252, 107-117.
37. Long, D. J. 2nd and Jaiswal, A. K. (2000). NRH:quinone oxidoreductase2 (NQO2). Chem Biol Interact, 129, 99-112.
38. Long, D. J. 2nd., Iskander, K., Gaikwad, A., Arin, M., Roop, D.R., Knox, R., Barrios, R. and Jaiswal, A. K. (2002) Disruption of dihydronicotinamide riboside: quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem, 277, 46131-46139.
39. Mailliet, F., Ferry, G., Vella, F., Berger, S., Cogé, F., Chomarat, P., Mallet, C., Guénin, S. P., Guillaumet, G., Viaud-Massuard, M. C., Yous, S., Delagrange, P. and Boutin, J. A. (2005). Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem Pharmacol, 71, 74-88.
40. Nelson, M. J., Brennan, B. A., Chase, D. B., Cowling, R. A, Grove G. N. and Scarrow, R. C. (1995). Structure and kinetics of formation of catechol complexes of ferric soybean lipoxygenase-1. Biochemistry, 34, 15219-15229.
41. Ohgake, S., Hashimoto, K., Shimizu, E., Koizumi, H., Okamura, N., Koike, K., Matsuzawa, D., Sekine, Y., Inada, T., Ozaki, N., Iwata, N., Harano, M., Komiyama, T., Yamada, M., Sora, I., Ujike, H., Shirayama, Y. and Iyo, M. (2005). Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis. Addict Biol, 10, 145-148.
42. Okada, S., Farin, F. M., Stapleton, P., Viernes, H., Quigley, S. D, Powers, K. M., Smith-Weller, T., Franklin, G. M., Longstreth, W. T, Swanson, P. D. and Checkoway, H. No associations between Parkinson's disease and polymorphisms of the quinone oxidoreductase (NQO1, NQO2) genes. Neurosci Lett, 375, 178-180.
43. Okubo, T., Harada, S., Higuchi, S. and Matsushita, S. (2003). Association analyses between polymorphisms of the phase II detoxification enzymes (GSTM1, NQO1, NQO2) and alcohol withdrawal symptoms. Alcohol Clin Exp Res, (8 Suppl):68S-71S.
44. Panoutsopoulos, G. I. and Beedham, C. (2004). Kinetics and specificity of guinea pig liver aldehyde oxidase and bovine milk xanthine oxidase towards substituted benzaldehydes. Acta Biochim Pol, 51, 649-663.
45. Payton, A., Miyajima, F., Ollier, W., Rabbitt, P., Pickles, A., Weiss, V., Pendleton, N. and Horan, M. (2010). Investigation of a functional quinine oxidoreductase (NQO2) polymorphism and cognitive decline. Neurobiol Aging, 31, 351-352.
46. Roy, D., Bernhardt, A., Strobel, H. W., Liehr, J. G. (1992). Catalysis of the oxidation of steroid and stilbene estrogens to estrogen quinone metabolites by the beta-naphthoflavone-inducible cytochrome P450 IA family. Arch Biochem Biophys, 296, 450-456.
47. Reybier, K., Perio, P., Ferry, G., Bouajila, J., Delagrange, P. and Boutin, J. A. and Nepveu, F. (2011). Insights into the redox cycle of human quinone reductase 2. Free Radic Res, 45, 1184-1195.
48. Sampaio, L. F. S. (2009). An unexpected effect of 5-MCA-NAT in chick retinal development. Int J Dev Neurosci, 27, 511-515.
49. Sampaio, R. V., Conceição, S. D., Miranda, M. S., Sampaio, L. F. S. and Ohashi, O. M. (2012). MT3 melatonin binding site, MT1 and MT2 melatonin receptors are present in oocyte, but only MT1 is present in bovine blastocyst produced in vitro. Reprod Biol Endocrinol, 10(1):103.
50. Shen, J., Barrios, R. J. and Jaiswal, A. K. (2010). Inactivation of the quinone oxidoreductases NQO1 and NQO2 strongly elevates the incidence and multiplicity of chemically induced skin tumors. Cancer Res, 70, 1006-1014.
51. Siegbahn, P. E. (2004). The catalytic cycle of catechol oxidase. J Biol Inorg Chem, 9, 577-590.
52. Strassburg, A., Strassburg, C. P., Manns, M. P. and Tukey, R. H. (2002). Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. Mol Pharmacol, 61, 320-325.
53. Tse, D. C., McCreery, R. L. and Adams, R. N. (1976). Potential oxidative pathways of brain catecholamines. J Med Chem, 19, 37-40.
54. Vella, F., Ferry, G., Delagrange, P. and Boutin J. A. (2005). NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol, 71, 1-12.
55. Venugopal, D., Zahid, M., Mailander, P. C., Meza, J. L, Rogan, E. G., Cavalieri, E. L. and Chakravarti, D. (2008). Reduction of estrogeninduced transformation of mouse mammary epithelial cells by Nacetylcysteine. J Steroid Biochem Mol Biol, 109, 22-30.
56. Volpicelli-Daley, L. A., Luk, K. C., Patel, T. P., Tanik, S. A., Riddle, D. M., Stieber, A., Meaney, D. F., Trojanowski, J. Q. and Lee, V. M. (2011). Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron, 72, 57-71.
57. Yu, K. D., Di, G. H., Yuan, W. T., Fan, L., Wu, J., Hu, Z., Shen, Z. Z., Zheng, Y., Huang, W. and Shao, Z. M. (2009) Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum Mol Genet, 18, 2502-2517.
58. Wang, M. Y. and Liehr, J. G. (1994). Identification of fatty acid hydroperoxide cofactors in the cytochrome P450-mediated oxidation of estrogens to quinone metabolites. Role and balance of lipid peroxides during estrogen-induced carcinogenesis. J Biol Chem, 269, 284-291.
59. Wang, W. and Jaiswal A. K. (2004) Sp3 repression of polymorphic human NRH:quinone oxidoreductase 2 gene promoter. Free Radic Biol Med, 37, 1231-1243.
60. Wang, W., Le, W. D., Pan, T., Stringer, J. L. and Jaiswal, A. K. (2008). Association of NRH:quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson's disease. J Gerontol A Biol Sci Med Sci, 63, 127-134.
61. Whitehead, R. E., Ferrer, J. V., Javitch, J. A. and Justice, J. B. (2001). Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J. Neurochem., 76, 1242-1251.
62. Zahid, M., Saeed, M., Rogan, E. G. and Cavalieri, E. L. (2010). Benzene and dopamine catechol quinones could initiate cancer or neurogenic disease. Free Radic Biol Med, 48, 318-324.
63. Zahid, M., Saeed, M., Ali, M. F., Rogan, E. G. and Cavalieri, E. L. (2010) Nacetylcysteine blocks formation of cancer-initiating estrogen-DNA adducts in cells. Free Radic Biol Med, 49, 392-400.
64. Zahid, M., Saeed, M., Yang, L., Beseler, C., Rogan, E. and Cavalieri, E. L. (2011). Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease. IUBMB Life. 63, 1087-1093.
65. Zahid, M., Saeed, M., Beseler, C., Rogan, E. G. and Cavalieri, E. L. (2011) Resveratrol and N-acetylcysteine block the cancer-initiating step in MCF-10F cells. Free Radic Biol Med, 50, 78-85.
66. Zhang, Y., Gaikwad, N. W., Olson, K., Zahid, M., Cavalieri, E. L. and Rogan, E. G. (2007). Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism, 56, 887-894.
67. Zhou, Z. D. and Lim, T. M. (2010). Glutathione conjugates with dopamine derived quinones to form reactive or non-reactive glutathione-conjugates. Neurochem Res, 35, 1805-1818.
68. Zhu, B. T. and Liehr, J. G. (1994). Quercetin increases the severity of estradiol-induced tumorigenesis in hamster kidney. Toxicol Appl Pharmacol, 125, 149-158.
69. Zmijewski, M. A., Sweatman, T. W. and Slominski, A. T. (2009). The melatonin-producing system is fully functional in retinal pigment epithelium (ARPE-19). Mol Cell Endocrinol, 307, 211-216.